公开(公告)号：WO1994015464A1

公开(公告)日：1994-07-21

申请号：PCT/US1994000617

申请日：1994-01-13

Applicant: ABBOTT LABORATORIES

Inventor： ABBOTT LABORATORIES ,  DEMICHELE, Stephen, Joseph ,  KARLSTAD, Michael, Donald ,  BISTRIAN, Bruce, Ryan ,  MASCIOLI, Edward, Anthony

IPC: A01N37/06

CPC classification number: C07C69/587 ,  A23L33/115 ,  A23L33/12 ,  A61K31/23 ,  A61K31/232

Abstract: There is disclosed structured lipid containing either a gamma-linolenic acid or a dihomogamma-linolenic acid residue, together with an n-3 fatty acid residue and a medium chain fatty acid residue on the same glycerol backbone. This structured lipid is particularly well adapted to the treatment of disease or stress states. The gamma-linolenic or dihomogamma-linolenic acid residues modify the prostanoid synthesis pathway, reducing the level of series "2" prostanoids and elevating the levels of series "1" and "3" prostanoids. The n-3 fatty acid residue enhances the level of series "1" prostanoids as well as increases the production of series "3" prostanoids. The medium chain fatty acid residues enhances the absorption of the structured lipid. There is also disclosed enteral and parenteral diets as well as nutritional supplements containing the structured lipids of the invention.

Abstract translation: 公开了在同一甘油主链上含有γ-亚麻酸或二亚麻酸 - 亚麻酸残基以及n-3脂肪酸残基和中链脂肪酸残基的结构化脂质。 这种结构化脂质特别适用于治疗疾病或应激状态。 γ-亚麻酸或二亚麻酸亚麻酸残基改变前列腺素合成途径，降低“2”前列腺素类的水平，提高“1”和“3”前列腺素类的水平。 n-3脂肪酸残基提高了“1”型前列腺素类的水平，并增加了“3”型前列腺素类的产生。 中链脂肪酸残基增强了结构化脂质的吸收。 还公开了肠内和肠胃外饮食以及含有本发明的结构化脂质的营养补充剂。

公开(公告)号：EP0679057A1

公开(公告)日：1995-11-02

申请号：EP94906082.0

申请日：1994-01-13

Applicant: ABBOTT LABORATORIES

Inventor： DEMICHELE, Stephen, Joseph ,  KARLSTAD, Michael, Donald ,  BISTRIAN, Bruce, Ryan ,  MASCIOLI, Edward, Anthony

IPC: A23L1 ,  A61K31 ,  C07C69

CPC classification number: C07C69/587 ,  A23L33/115 ,  A23L33/12 ,  A61K31/23 ,  A61K31/232

Abstract: There is disclosed structured lipid containing either a gamma-linolenic acid or a dihomogamma-linolenic acid residue, together with an n-3 fatty acid residue and a medium chain fatty acid residue on the same glycerol backbone. This structured lipid is particularly well adapted to the treatment of disease or stress states. The gamma-linolenic or dihomogamma-linolenic acid residues modify the prostanoid synthesis pathway, reducing the level of series '2' prostanoids and elevating the levels of series '1' and '3' prostanoids. The n-3 fatty acid residue enhances the level of series '1' prostanoids as well as increases the production of series '3' prostanoids. The medium chain fatty acid residues enhances the absorption of the structured lipid. There is also disclosed enteral and parenteral diets as well as nutritional supplements containing the structured lipids of the invention.

公开(公告)号：EP0679057B1

公开(公告)日：1999-08-18

申请号：EP94906082.6

申请日：1994-01-13

Applicant: ABBOTT LABORATORIES

Inventor： DEMICHELE, Stephen, Joseph ,  KARLSTAD, Michael, Donald ,  BISTRIAN, Bruce, Ryan ,  MASCIOLI, Edward, Anthony

IPC: A01N37/06 ,  A61K31/22 ,  C07C69/587

CPC classification number: C07C69/587 ,  A23L33/115 ,  A23L33/12 ,  A61K31/23 ,  A61K31/232

Abstract: There is disclosed structured lipid containing either a gamma-linolenic acid or a dihomogamma-linolenic acid residue, together with an n-3 fatty acid residue and a medium chain fatty acid residue on the same glycerol backbone. This structured lipid is particularly well adapted to the treatment of disease or stress states. The gamma-linolenic or dihomogamma-linolenic acid residues modify the prostanoid synthesis pathway, reducing the level of series "2" prostanoids and elevating the levels of series "1" and "3" prostanoids. The n-3 fatty acid residue enhances the level of series "1" prostanoids as well as increases the production of series "3" prostanoids. The medium chain fatty acid residues enhances the absorption of the structured lipid. There is also disclosed enteral and parenteral diets as well as nutritional supplements containing the structured lipids of the invention.